Citigroup Inc Sigilon Therapeutics, Inc. Transaction History

Citigroup Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.74 - $1.64 $570 - $1,264	-771 Reduced 63.09%	451 $0
Q1 2022 May 12, 2022	SELL	$1.24 - $3.03 $3,312 - $8,093	-2,671 Reduced 68.61%	1,222 $2,000
Q4 2021 Feb 10, 2022	BUY	$2.58 - $6.13 $5,570 - $13,234	2,159 Added 124.51%	3,893 $11,000
Q3 2021 Nov 10, 2021	BUY	$4.42 - $10.61 $7,664 - $18,397	1,734 New	1,734 $10,000

Ticker SGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,399,300
Description
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neuro...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.